Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Good review of Akero

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on May 18, 2021 12:08pm

101 Views

Post# 33222267

RE:RE:Good review of Akero

They did in Nov 2020 and May 2020

https://seekingalpha.com/article/4391925-theratechnologies-canadian-market-stage-company-late-stage-pipeline

scarlet1967 wrote:

The article was written by these guys again it would be great for THTX to get coverage like this from these people, they have 13.91K Followers.

“Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.

Avisol Capital Partners is a top contributor on SeekingAlpha. Total Pharma Tracker is our marketplace service on SeekingAlpha.”

SPCEO1 wrote: Given the evidence that Akero's drug may be helpful with Firbrosis, maybe a combination of Egrifta and their drug would turnin better results.

https://seekingalpha.com/article/4427263-akero-therapeutics-a-nash-pureplay-with-differentiated-mid-stage-data?mail_subject=avisol-capital-partners-akero-therapeutics-a-nash-pureplay-with-differentiated-mid-stage-data&utm_campaign=rta-author-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha